Healthcare resource utilization and payer cost analysis of patients with prurigo nodularis.

Abstract

Prurigo nodularis (PN) is a chronic dermatosis characterized by severely pruritic nodules on the trunk and extensor surfaces. In addition to its skin manifestations, PN is also associated with a variety of systemic conditions.1,2,3 Furthermore, many patients with PN are refractory to therapy with no FDA-approved agents available to date.4 Despite challenges in management and a significant burden of comorbidities in PN, there are limited studies examining healthcare utilization in this condition.5 Herein we use a medical claims from a large, ambulatory cohort to describe real-world healthcare utilization and economic burden in PN.